All Articles

Time to Complete Oncology Pharmacist Tasks: A Joint Opinion of HOPA and American College of Clinical Pharmacy's Hematology/Oncology Practice and Research Network
HOPA and the Hematology/Oncology Practice and Research Network (PRN) of the ACCP published research producing the first comprehensive consensus statements on the average time for a U.S.-based oncology pharmacist to complete common care-related tasks.

Together We Can Save Cancer Research - and Lives
In the past two decades, extraordinary progress has been made in the fight against cancer. However, with Congress determined to reduce federal spending, entire cancer research, prevention, and surveillance programs are on the verge of elimination.


Pharmacist's Application to Practice: Remestemcel-L-rknd
Erin Lexner, PharmD, BCPS, PGY-2 Oncology Pharmacy Resident, and Christine Barrett, PharmD, BCOP, Oncology Pharmacy Specialist - both from Mary Babb Randolph Cancer Center at West Virginia University Hospitals - write about remestemcel-L-rknd.

Late-Breaking HOPA News: The Emerging Use of Bispecific Antibodies with Chemotherapy in Diffuse Large B-Cell Lymphoma
Katelynn Granger, PharmD, BCOP, and Matthew Warrick, PharmD, BCPS, BCOP, dive into the emerging use of bispecific antibodies with chemotherapy in diffuse large B-cell lymphoma.

Pharmacist's Application to Practice: Mirdametinib
Ramsey Shane, PharmD, MPH, PGY1 Pharmacy Resident, and Rebecca Pokorny, PharmD, BCPS, BCOP, Clinical Pharmacist Specialist Neuro-Oncology - both from Vanderbilt University Medical Center, Nashville, TN - write about mirdametinib (Gomekli).

Pharmacist's Application to Practice: Ensartinib
Savannah Young, PharmD, PGY1 Pharmacy Resident, from Sarasota Memorial Hospital, Sarasota, FL, and Kiera Roubal, PharmD, BCOP, Clinical Oncology Pharmacist Specialist, from Medical University of South Carolina, Charleston, SC, write about ensartinib.